The specific biochemical reaction that initiated the process was the direct, non-covalent binding of the causative drug to a specific Human Leukocyte Antigen (HLA) protein variant, creating a novel three-dimensional structure that was then recognized as foreign by the patient's T-cells, triggering a massive, misdirected immune response against skin cells.